ORIN — The Oral Insulin Network

ORIN establishes a neutral evidence network specifically for oral insulin. Key features include: * Facilitating research and development collaboration * Providing a public record of clinical trial outcomes * Supporting regulatory and commercial pathways * Aiming for needle-free insulin delivery This network connects researchers, developers, manufacturers, clinicians, payers, and capital providers to evaluate and advance oral insulin technologies. By focusing on protection, release, and delivery mechanisms, ORIN addresses the complexities of transforming insulin into an effective oral medication, bypassing traditional injection methods. The initiative seeks to bridge the gap between public perception and scientific evidence regarding oral insulin, ensuring transparency and accountability in its development. It aims to create a robust, verifiable account of any oral insulin program's progress and efficacy, moving beyond preliminary reports to focus on tangible, regulator-approved outcomes. ORIN is ideal for stakeholders in pharmaceutical development, biotechnology research, and healthcare investment who are focused on diabetes care and novel drug delivery systems. It serves as a vital platform for accelerating the development and adoption of successful oral insulin therapies.